New drug duo aims to shrink stomach tumors before surgery

NCT ID NCT07315035

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase II trial tests whether adding a new immunotherapy drug (QL1706) to standard chemotherapy (SOX) before surgery can completely eliminate stomach cancer in patients with a specific, aggressive type. About 74 adults with stage III diffuse-type gastric cancer will be randomly assigned to receive either the combo or chemo alone before their stomach removal surgery. The main goal is to see if the combo leads to a higher rate of complete tumor disappearance by the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QL1706 (Iparomlimab/Tuvonralimab) combined with SOX chemotherapy
What this could lead to: If successful, this could lead to a more effective pre-surgery treatment for a hard-to-treat stomach cancer, potentially improving outcomes after surgery.
What could go wrong: This is an early Phase II trial with only 74 participants, so results may not apply broadly. Adding immunotherapy to chemo can cause more side effects, and the treatment may not improve response rates as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates